698
Participants
Start Date
April 18, 2014
Primary Completion Date
March 11, 2015
Study Completion Date
March 11, 2015
Dalbavancin
Dalbavancin IV infusion over 30 minutes.
Dalbavancin-matching Placebo
Dalbavancin-matching placebo IV infusion over 30 minutes.
802, Sofia
751, Middleburg
800, Sofia
801, Sofia
755, Johannesburg
756, Breyten
752, Dundee
352, Debrecen
302, Kutaisi
758, Port Elizabeth
351, Szeged
754, Worcester
353, Kaposvár
760, Cape Town
354, Pécs
200, Zagreb
201, Zagreb
253, Tallinn
600, Belgrade
601, Belgrade
252, Tallinn
603, Niš
700, Cherkasy
112, Washington D.C.
602, Novi Sad
114, Augusta
125, Savannah
122, Columbus
107, Orlando
120, Saint Cloud
110, Montgomery
126, Franklin
127, Smyrna
503, Bucharest
111, Toledo
109, Detroit
704, Dnipropetrovsk
251, Tartu
121, Butte
705, Kharkiv
123, Omaha
702, Zaporizhzhya
119, Eunice
706, Ivano-Frankivsk
701, Ivano-Frankivsk
703, Lviv
117, Long Beach
106, Long Beach
105, Sylmar
104, San Diego
113, San Diego
115, San Diego
116, San Diego
103, Anaheim
108, Stockton
118, Modesto
552, Moscow
554, Moscow
555, Vsevolozhsk
551, Saint Petersburg
501, Cluj-Napoca
553, Novosibirsk
556, Tomsk
557, Irkutsk
101, Springfield
303, Tbilisi
300, Tbilisi
301, Tbilisi
402, Daugavpils
401, Liepāja
403, Rēzekne
400, Riga
404, Riga
502, Bucharest
500, Bucharest
757, Pretoria
753, Pretoria
759, Pretoria
Durata Therapeutics Inc., an affiliate of Allergan plc
INDUSTRY